VVOS News and Press, Vivos Therapeutics Inc. From 10/06/21

Nemours Children’s Health director of preventive cardiology Dr. Carissa Baker-Smith stated in a recent interview that disrupted and poor sleep in children could be linked to difficulty focusing in the daytime. This, she added, could negatively affect their performance in school. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! Get ready for another busy day of trading today with a look at the biggest pre-market stock movers for Wednesday! Source: oneinchpunch/Shutterstock.com News moving stocks this morning range f...

When one is asleep, the body’s muscles, which include the chest and throat muscles that help in breathing, relax. Obstructive sleep apnea is a sleep disorder that causes breathing to stop involuntarily as individuals sleep. The disorder may cause individuals to wake up with a dry ...

HIGHLANDS RANCH, Colo., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-t...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairma...

HIGHLANDS RANCH, Colo., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients ...

Sleep apnea is a common and serious sleep disorder that affects an individual’s breathing during sleep. Undiagnosed and untreated sleep apnea can worsen an individual’s mood, raise their blood pressure and even stress the heart . Some people suffering from this disorder us...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 2...

Vivos management to present at 7:00 am EDT on September 13, 2021 HIGHLANDS RANCH, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovati...

Research conducted by Penn State College of Medicine has discovered that individuals who are diagnosed with obstructive sleep apnea have a higher risk of sudden death in comparison with individuals who don’t have sleep apnea. Estimates show that more than one billion people global...